Goldman's LBO, PSAV, failed to price this week and officially postponed its offering on Friday, reflecting the uncertain environment currently faced by investors. The IPO market is struggling to build momentum amid market volatility and macroeconomic disturbances. Along with continued talks of a Brexit, the Fed declined to raise rates again, and the VIX Volatility Index...read more
Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, raised $14 million by offering 2.7 million shares at $5. The company, which was listed on the OTCQB under the symbol VIVMF, had expected to raise $12.5 million by offering 1.56 million shares at $8 per share. Viveve Medical plans to list on the Nasdaq under the symbol VIVE....read more
The week ahead will see three IPOs, led by Goldman LBO PSAV which will be accompanied by two smaller deals that are already OTC listed. IPO activity is still sluggish, but the gradual increase in trailing 90 day IPO returns over the past month (from 5.6% to 13%) and IPO index outperformance over the past month (+2% vs. S&P +1.6%) may help increase the number of...read more
Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, announced terms for its IPO on Thursday. The Sunnyvale, CA-based company plans to raise $12.5 million by offering 1.6 million shares at a price of $8. At the midpoint of the proposed range, Viveve Medical would command a fully diluted market value of $73 million. Viveve...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
US IPO Weekly Recap: Goldman's LBO postpones
Goldman's LBO, PSAV, failed to price this week and officially postponed its offering on Friday, reflecting the uncertain environment currently faced by investors. The IPO market is struggling to build momentum amid market volatility and macroeconomic disturbances. Along with continued talks of a Brexit, the Fed declined to raise rates again, and the VIX Volatility Index...read more
Early-stage device maker Viveve Medical prices upsized Nasdaq IPO below expectations at $5
Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, raised $14 million by offering 2.7 million shares at $5. The company, which was listed on the OTCQB under the symbol VIVMF, had expected to raise $12.5 million by offering 1.56 million shares at $8 per share. Viveve Medical plans to list on the Nasdaq under the symbol VIVE....read more
US IPO Week Ahead: Goldman LBO leads the way
The week ahead will see three IPOs, led by Goldman LBO PSAV which will be accompanied by two smaller deals that are already OTC listed. IPO activity is still sluggish, but the gradual increase in trailing 90 day IPO returns over the past month (from 5.6% to 13%) and IPO index outperformance over the past month (+2% vs. S&P +1.6%) may help increase the number of...read more
Microcap medical device maker Viveve Medical sets terms for $13 million IPO
Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, announced terms for its IPO on Thursday. The Sunnyvale, CA-based company plans to raise $12.5 million by offering 1.6 million shares at a price of $8. At the midpoint of the proposed range, Viveve Medical would command a fully diluted market value of $73 million. Viveve...read more